Income Statement
X4 PHARMACEUTICALS, INC
XFOR
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Revenue
|
35.11 | 2.60 | - | 0.00 | 0.00 | 3.00 | - | 3.50 |
|
Cost of Revenue
|
5.76 | 0.80 | - | - | - | - | - | - |
|
Gross Profit
|
29.36 | 1.80 | - | - | - | 3.00 | - | 3.50 |
|
Operating Expenses
|
116.24 | 143.16 | 107.52 | 87.57 | 85.11 | 62.87 | 51.70 | 49.39 |
|
Research & Development
|
72.72 | 81.64 | 72.02 | 61.06 | 50.65 | 41.93 | 30.16 | 30.98 |
|
Selling, General & Administrative
|
43.52 | 61.52 | 35.51 | 27.02 | 24.70 | 20.94 | 17.64 | 18.41 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - |
|
Operating Income
|
-86.88 | -141.36 | -107.52 | -87.57 | -85.11 | -59.87 | -51.70 | -45.89 |
|
Non-Operating Income
|
7.73 | -0.74 | 6.43 | -6.27 | -3.57 | -2.11 | -1.10 | 2.86 |
|
Interest Income
|
4.58 | 5.77 | 4.58 | 0.22 | 0.01 | 0.27 | 1.20 | 0.81 |
|
Interest Expense
|
8.88 | 8.77 | 5.78 | 3.99 | 3.64 | 2.70 | 2.15 | 1.04 |
|
Other Non-Op Income / Expense
|
0.00 | 0.70 | 0.60 | 0.50 | 0.80 | 0.91 | 0.52 | -0.09 |
|
Income Before Tax
|
-79.16 | -37.14 | -101.09 | -93.84 | -88.68 | -61.98 | -52.81 | -43.02 |
|
Income Tax Expense
|
0.04 | 0.31 | 0.08 | 0.03 | 0.02 | 0.15 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - |
|
Net Income
|
-79.20 | -37.45 | -101.17 | -93.87 | -88.70 | -62.13 | -52.81 | -43.02 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - |
|
EBITDA
|
-85.61 | -140.56 | -107.10 | -87.06 | -84.61 | -59.52 | -51.60 | -45.73 |
|
Earnings Per Share (Basic)
|
-1.87 | -0.19 | -0.57 | -1.52 | - | - | - | - |
|
Diluted EPS
|
-1.87 | -0.19 | -0.57 | -1.52 | - | - | - | - |
|
Weighted Average Shares
|
42.29 | 201.06 | 177.81 | 63.53 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
42.29 | 201.06 | 177.81 | 63.53 | - | - | - | - |
|
Comprehensive Income
|
- | -37.45 | - | - | -88.70 | -62.13 | -52.93 | -42.91 |